UCLA Broad Stem Cell Research Center

What UCLA Broad Stem Cell Research Center does

The UCLA Broad Stem Cell Research Center (officially the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA) is a non-profit academic research center established in 2005 and housed within the University of California, Los Angeles. The center operates as a collaborative research hub that brings together 250+ affiliated faculty members from 55 schools and departments, 385 trainees, and a 42-person core staff to advance stem cell biology, regenerative medicine, cell and gene therapy, and organoid technology. Its primary constituents are academic researchers, trainees, and patients enrolled in 50+ active clinical trials; it does not sell commercial products or services.

Core technical capabilities span proprietary platforms including the Artificial Thymic Organoid (Crooks/Seet) for T cell development, 3D lung organoids and the Scar-in-a-Dish fibrosis model (Gomperts), Nanovial single-cell analysis technology (Di Carlo), and Disease-in-a-Dish models. Infrastructure assets include the 14,000-square-foot FDA-compliant Center for Advanced Biotherapies, which nearly doubles UCLA's capacity to manufacture clinical-grade cell and gene therapies. The therapeutic pipeline includes AD-NP1, an ENPP1-blocking monoclonal antibody that received FDA Phase 1 approval in September 2025 for heart tissue regeneration and has shown preclinical efficacy in kidney repair.

The center's economic model is grant-funded rather than commercial: primary revenue streams are research grants (CIRM, NIH, DoD), philanthropy (Broad Foundation, Michelson Medical Research Foundation), and strategic partner funding (Chan Zuckerberg Initiative). Research outputs flow to patients through clinical trials, to the scientific community through publications, and to industry through technology licensing and 28 launched spinout companies. Recent strategic moves include the 2025 opening of the Center for Advanced Biotherapies, the FDA approval of AD-NP1, the 2026 launch of the Billion Cell×Cell Project with CZI, and the addition of new faculty including computational protein design investigator Mohamad Abedi.

Name

UCLA Broad Stem Cell Research Center

Legal name

Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA

Website

https://stemcell.ucla.edu

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

The UCLA Broad Stem Cell Research Center is a non-profit academic research hub at UCLA, founded 2005, uniting 250+ faculty and 385 trainees to develop stem cell therapies, organoid models, and FDA-compliant cell and gene therapy manufacturing for clinical trials and 28 launched spinout companies.

Ownership category

akta.pro rank

Product category

Stem Cell and Regenerative Medicine Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Technology Transfer & Innovation-Driven Research Universities (High Commercialization) (EDAHABAH)

Keywords

• Stem cell research
• Regenerative medicine
• Cell and gene therapy
• Organoid technology
• Biomedical research

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. Research Grants and Funding: Primary funding from grants including CIRM (California Institute for Regenerative Medicine), National Institutes of Health, and Department of Defense. Center also receives philanthropic support and manages funding programs for members.
2. Spinout Companies: Center has launched 28 spinout companies from research discoveries, generating potential licensing revenue and equity returns.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

The UCLA Broad Stem Cell Research Center is a non-profit academic research center that conducts and supports stem cell, regenerative medicine, and cell/gene therapy research. It provides shared research infrastructure (notably the FDA-compliant Center for Advanced Biotherapies manufacturing facility), runs 50+ active clinical trials, develops proprietary research platforms such as organoid models and the Nanovial single-cell tool, and trains the next generation of stem cell scientists.

Product overview

The UCLA Broad Stem Cell Research Center operates as a research center that provides infrastructure and resources for stem cell and regenerative medicine research. Its core offerings include the Center for Advanced Biotherapies, a 14,000-square-foot FDA-compliant manufacturing facility for producing cell and gene therapies; proprietary 3D organoid models (lung organoids, artificial thymic organoids); the scar-in-a-dish fibrosis model; the nanovial platform for single-cell analysis; and disease-in-a-dish models. The center also advances the Billion Cell×Cell Project for mapping cellular communications and develops therapeutic candidates like AD-NP1 for tissue regeneration.

Differentiator

Problem solved

Functional benefit

Products and services

• Center for Advanced Biotherapies 14,000-square-foot FDA-compliant manufacturing facility that produces clinical-grade cell and gene therapies — including personalized cancer vaccines and stem cell gene therapies — for patients enrolled in the center's clinical trials. Used by UCLA researchers and partner investigators to manufacture trial-stage therapies.
• AD-NP1 (ENPP1-blocking antibody) Monoclonal antibody therapeutic candidate engineered to target and block the ENPP1 protein, which disrupts tissue repair after injury. Developed by Arjun Deb's lab at UCLA for heart tissue regeneration, now in FDA-approved Phase 1 clinical trials, with preclinical evidence supporting use in kidney tissue repair.
• Clinical Trials Program Program running 50+ active clinical trials for stem cell, regenerative medicine, and cell/gene therapy interventions. Open to patients with conditions including heart tissue damage, kidney injury, cancer (immunotherapy), multiple sclerosis, and fibrotic diseases.
• Billion Cell×Cell Project Large-scale scientific consortium initiative (with USC, Caltech, and the Chan Zuckerberg Initiative) to generate nearly 1 billion measurements of controlled cell-cell interactions, building a reference dataset for understanding cellular communication in health and disease. Provides resources and collaboration opportunities for the scientific community.
• Training and Education Programs Formal training programs and educational resources for graduate students, postdoctoral researchers, and early-career scientists in stem cell biology and regenerative medicine. Includes the High School Outreach Program that has reached 1,268+ students and ongoing mentorship for 385 trainees.

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core, major and minor.

• University of Southern California (USC)coreStrategic or Co-development Partner · 23 June 2026UCLA and USC researchers collaborated on the Billion Cell×Cell Project, with USC scientists Leonardo Morsut, Megan L. McCain, Eunji Chung and Yingxiao Wang contributing to the perspective published in Nature Biotechnology.
• California Institute of Technology (Caltech)coreStrategic or Co-development Partner · 23 June 2026UCLA and Caltech researchers collaborated on the Billion Cell×Cell Project, with Caltech scientists Long Cai, Matt Thomson and Michael Elowitz contributing to the perspective on decoding cellular conversations.
• Cold Spring Harbor LaboratorymajorStrategic or Co-development Partner · 23 June 2026Dr. David Tuveson of Cold Spring Harbor Laboratory delivering keynote address at UCLA JCCC Organoid Symposium, highlighting impactful research in the organoid community.
• California Science CenterminorStrategic or Co-development PartnerHosting venue for 2026 Geroscience Los Angeles Meeting (GLAM), a trainee-focused meeting uniting the geroscience community in the greater Los Angeles area.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Gladstone Institutes: San Francisco-based non-profit research organization affiliated with UCSF that conducts stem cell, iPSC and disease-in-a-dish research with direct overlap to UCLA BSCRC's disease modeling and regenerative medicine programs.
• Scripps Research: Non-profit research institute with significant programs in regenerative medicine, chemistry-based therapeutics and cell biology that compete with UCLA BSCRC for grants, trainees and industry partnerships.
• MIT Koch Institute for Integrative Cancer Research: MIT's cancer-focused research institute working on immunoengineering, nanotechnology and cell therapies — overlapping with UCLA BSCRC's nanovial platform, cancer immunotherapy trials and cell therapy manufacturing.
• Cold Spring Harbor Laboratory: Long-standing biomedical research institute with overlapping programs in cancer, neuroscience and cell biology; collaborates with UCLA BSCRC (e.g., David Tuveson keynote) and competes for elite faculty and trainees.
• UCSF Bakar Aging Research Institute / Regenerative Medicine Programs: UCSF's broader portfolio of regenerative medicine and aging research, which overlaps with UCLA BSCRC's stem cell and gene therapy work and competes for CIRM funding, faculty recruits and Bay Area talent.

Direct peers

• Harvard Stem Cell Institute: Interdisciplinary stem cell research institute at Harvard that mirrors UCLA BSCRC's model of convening faculty across departments to translate stem cell science into clinical therapies, making it a direct competitor for talent and funding.
• Parker Institute for Cancer Immunotherapy: Multi-institution consortium focused on cancer immunotherapy including cell therapies; UCLA BSCRC faculty (Owen Witte) co-direct the UCLA Parker Institute, making it both a partner and a programmatic peer.
• Stanford Institute for Stem Cell Biology and Regenerative Medicine: University-based stem cell and regenerative medicine institute at Stanford that conducts overlapping organoid, cell therapy and disease modeling research and competes for the same NIH/CIRM grants, faculty and spinouts.

Emerging players

• Chan Zuckerberg Biohub: CZI-funded research organization advancing cellular biology, imaging and cell-cell interaction mapping that parallels the Billion Cell×Cell Project and shares a common CZI funding source with UCLA BSCRC.
• Allen Institute for Cell Science: Non-profit research division creating dynamic, visualizable iPSC-derived cell models and datasets — directly comparable to UCLA BSCRC's disease-in-a-dish, organoid and Billion Cell×Cell programs at the cell biology platform layer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ucla-broad-stem-cell-research-center

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UCLA Broad Stem Cell Research Center